Navigation Links
Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors
Date:4/18/2013

CASTLE ROCK, Colo., April 18, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, protein biomarker-based assay for appendicitis, today announced the appointment of Stephen A. Williams , M.D., Ph.D., Chief Medical Officer at SomaLogic, to the Company's Board of Directors.  Dr. Williams brings his experience in diagnostic imaging and biomarker discovery to the Venaxis Board.

Steve Lundy , President and CEO of Venaxis, stated, "We are happy to welcome Steve to our Board and look forward to the benefit of his deep experience, both in diagnostic imaging, which is relevant to our market development and commercial strategy for the APPY1 Test, as well as in clinical biomarker validation, which will be instrumental to us in our evaluation and development of future Venaxis products."

Dr. Williams stated, "The APPY1 Test is an excellent example of how characterization of clinically relevant biomarkers can produce useful tools for addressing important diagnostic challenges.  With the potential to reduce the safety risks associated with current diagnostic imaging techniques in the emergency setting, I believe there is significant clinical need and utility for the APPY1 Test.  I am excited to join the Venaxis Board and to support the further development and commercialization of this, as well as potential future, biomarker-based diagnostic products."

Dr. Williams joined SomaLogic in 2009 as Chief Medical Officer.  Prior to his time at SomaLogic, Dr. Williams trained as a physician at Charing Cross and Westminster Medical School, University of London, and following his internships, returned to the same institution for a Ph.D. in medicine and physiology.  He s
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AspenBio Pharma Changes Company Name to Venaxis, Inc.
2. Venaxis to Present at 2013 BIO CEO and Investor Conference
3. Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
4. Venaxis to Present at 25th Annual ROTH Conference
5. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
6. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
7. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
8. Nephros Appoints John C. Houghton as President and Chief Executive Officer
9. Elsevier Appoints New President of Elsevier CPM Resource Center
10. GenWay Biotech Appoints New Vice President of Custom/OEM
11. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 According to ... by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), ... - Global Analysis & Forecast to 2019", published by ... at $911.1 Million 2014 and is estimated to grow ... of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 4% as currency reduced sales growth ... per diluted share as reported (EPS) were $2.73, compared ... $2.80 , an increase of 9% over the ...
(Date:7/30/2015)... SAN DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... ended June 30, 2015.  Revenue for the quarter was ... quarter ended June 30, 2014 (a 17 percent increase ... million, consistent with the quarter ended June 30, 2014. ... consistent with the quarter ended June 30, 2014.  ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... the Phase III ZODIAC study in advanced non-small cell ... presented today at the American Society of Clinical Oncology ... met its primary endpoint, demonstrating that the addition of ... in progression-free survival (PFS), the length of time a ...
... at 45th American Society of Clinical Oncology Annual ... today announced results from Phase I and II ... inhibitor currently being studied in multiple tumor types. ... Annual Meeting of the American Society of Clinical ...
Cached Medicine Technology:Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 2Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 3Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 4Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 5Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506 2Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506 3
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium ... day each year is the Super Bowl. In the two weeks that separate the conference ... host venue. The 2016 Super Bowl game will mark the 50th time it has been ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... introduced its new store run by GoodThreads. The store can be accessed by ... and designs, many of which are customizable. The best part: whenever a product ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation ... Conference Center. The medical community, social workers, law enforcement, and government officials are ... in the effort to better understand and combat sex trafficking. Lead by sex ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... Rodgers Theatre . Those looking to catch a new and refreshing show on ... won numerous awards and achievements including an Obie Award, Outer Critics Circle Award, Drama ...
(Date:7/31/2015)... York (PRWEB) , ... July ... ... attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now available ... 2015 was well received with a 94% approval rating from the nationwide ...
Breaking Medicine News(10 mins):Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2
... , PRINCETON, N.J., Sept. 9 NephroGenex, Inc., ... announced the completion of patient enrollment in its Phase 2b clinical ... candidate Pyridorin(TM) (pyridoxamine dihydrochloride ) in type 2 diabetic patients ... have been randomized. , , The ...
... , , , ... -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ) ... Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in ... available in the United States for the treatment of pain and ...
... ... provide comprehensive security solution which includes PHARMORX,s new iPhone application for authentication and ... and diversion of products, within the pharmaceutical, food and beverage, cosmetic and consumer ... ...
... , , , ... 9 Research shows that 80 percent of cardiac events in women could ... exercise and abstinence from smoking. That,s why the American Heart Association,s Go Red ... yet life-saving - choices for their hearts in a new 30-minute NBC television ...
... PRINCETON, N.J., Sept. 9 Covance Inc. (NYSE: ... Weisel Partners 2009 Healthcare Conference on Thursday, September 10, 2009 at ... the presentation at www.covance.com . In order ... minutes early. , , Covance, with headquarters in ...
... , MURRIETA, Calif., Sept. 9 ... division provides drug and alcohol rehabilitation and a variety of ... announced today that Jerrod Menz, Forterus Vice President and co-founder ... Fent, Executive Vice President, will be interviewed on the VoiceAmerica ...
Cached Medicine News:Health News:NephroGenex Announces Full Enrollment in New Pyridorin(TM) Clinical Trial - PYR 210 2Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 2Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 3Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 4Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 5Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 6Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 7Health News:Providers of Packaging Design, Security Printing, and Track and Trace Technology Allign to Provide Multi-Layered Brand Protection Solution 2Health News:Providers of Packaging Design, Security Printing, and Track and Trace Technology Allign to Provide Multi-Layered Brand Protection Solution 3Health News:Providers of Packaging Design, Security Printing, and Track and Trace Technology Allign to Provide Multi-Layered Brand Protection Solution 4Health News:Providers of Packaging Design, Security Printing, and Track and Trace Technology Allign to Provide Multi-Layered Brand Protection Solution 5Health News:Go Red For Women and NBC Team Up to Help Women 'Choose to Live' 2Health News:Go Red For Women and NBC Team Up to Help Women 'Choose to Live' 3Health News:Go Red For Women and NBC Team Up to Help Women 'Choose to Live' 4Health News:Go Red For Women and NBC Team Up to Help Women 'Choose to Live' 5Health News:Forterus Inc. Executives to Be Interviewed on VoiceAmerica 2
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
... The Afinion HbA1c test and ... give you reliable facts conveniently ... need them. Advising the patient ... confidence. The HbA1c Test Cartridge ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
The Vivid e delivers everything you need in a compact echo system, like complete cardiovascular functionality, a comprehensive cardiac measurement and analysis package, and full shared service capabi...
Medicine Products: